2cureX has signed a distribution agreement with specialized diagnostic solutions leader Werfen, to distribute 2cureX products in SpainENDORESIST
- Novel drug targeting antiestrogen therapy resistance: a paradigm shift in breast cancer treatment
- ENDORESIST is a translational cancer research project which aims at seizing a major market opportunity by developing SCO-101, a new drug that targets anti-estrogen resistance in breast cancer. We will deliver a clinically validated and safe drug, and a companion diagnostic tool, opening the possibility to find a big pharma buyer/partner to capitalize on the SCO-101 opportunity. ENDORESIST builds around a patient-centric approach, based on biomarker discovery and insights on mechanisms of action.
- ENDORESIST not yet started and will run for 30 month.
- Partner to the ENDORESIST project are Scandion Oncology A/S and the Department of Medical Oncology of Erasmus MC, the University Medical Center Rotterdam. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.
![](https://www.2curex.com/wp-content/uploads/scandion.jpg")
![](https://www.2curex.com/wp-content/uploads/erasmus.jpg")
![](https://www.2curex.com/wp-content/uploads/eurostars.jpg")
Project Details
Acronym:
ENDORESIST
Duration:
36 months
Start date:
Not started
Topic:
New Treatments for Anti-estrogen Resistance
Funding:
2.2 Mio EUR
Upcoming events
December 7, 2021
CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)
December 9, 2021
2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)
January 20, 2022
2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)